A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)

被引：0
|
作者：
Rugo, H.
Tolaney, S.
Dickler, M.
Kabos, P.
Ho, C-L
Wildiers, H.
Jerusalem, G.
Ales-Martinez, J. E.
Hossain, A.
Johnston, E.
Gianni, L.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Univ Colorado, Anschutz Med Campus, Aurora, CO USA
[5] Tri Serv Gen Hosp, Natl Def Med Ctr, Taipei, Taiwan
[6] Univ Ziekenhuis Leuven Gasthuisbert, Leuven, Belgium
[7] Univ Sart Tilman, Ctr Hospitalier, Liege, Belgium
[8] Hosp Nuestra Senora Sonsoles, Complejo Hospitalario Avila Oncol, Avila, Spain
[9] Eli Lilly & Co, Indianapolis, IN 46285 USA
[10] IRCCS Osped, Milan, Italy
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-OT2-01-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-01-07
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive (HR+) HER2 negative (HER2-) breast cancer
    Li, Allen
    Naik, Arpana
    Johnson, Nathalie
    Goodyear, Shaun
    Johnson, Brett
    Park, Byung
    Corless, Christopher
    Gray, Joe
    Mills, Gordon
    Mitri, Zahi
    CANCER RESEARCH, 2021, 81 (04)
  • [2] Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study
    Rugo, Hope S.
    Kabos, Peter
    Beck, J. Thad
    Jerusalem, Guy
    Wildiers, Hans
    Sevillano, Elena
    Paz-Ares, Luis
    Chisamore, Michael J.
    Chapman, Sonya C.
    Hossain, Anwar M.
    Chen, Yanyun
    Tolaney, Sara M.
    NPJ BREAST CANCER, 2022, 8 (01)
  • [3] Abemaciclib for the treatment of HR+/HER2- breast cancer
    Exman, Pedro
    Tolaney, Sara M.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018, 3 (03): : 151 - 161
  • [4] COMPARISON OF HER2 mRNA PCR LEVELS AND IMMUNOHISTOCHEMISTRY (IHC) IN HORMONE RECEPTOR POSITIVE (HR+)/HER2 NEGATIVE (HER2-) EARLY BREAST CANCER
    Tejerina-Peces, Julia
    Amann-Arevalo, Marta
    Ballestin, Pablo
    Gonzalez-Diez, Beatriz
    Paz-Cabezas, Mateo
    Pascual, Alejandro
    de Luna, Alicia
    Garcia-Barberan, Vanesa
    Lopez de Sa, Alfonso
    Garcia-Saenz, Jose Angel
    Moreno, Fernando
    CANCER RESEARCH, 2024, 84 (09)
  • [5] Surgical Management of the Axilla in Patients Presenting with Clinically Node Positive Hormone Receptor Positive, HER2 Negative (HR+/HER2-) Breast Cancer
    Jasper, Jacob
    Kantor, Olga
    Dorninici, Laura
    Nakhlis, Faina
    Ogayo, Esther
    Nimbkar, Suniti
    Kurt, Busem Binbogct
    King, Tari
    Mittendorf, Elizabeth
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S101 - S101
  • [6] Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
    Hope S. Rugo
    Peter Kabos
    J. Thad Beck
    Guy Jerusalem
    Hans Wildiers
    Elena Sevillano
    Luis Paz-Ares
    Michael J. Chisamore
    Sonya C. Chapman
    Anwar M. Hossain
    Yanyun Chen
    Sara M. Tolaney
    npj Breast Cancer, 8
  • [7] Disease features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients
    Wang, Jinhao
    Liu, Yaxin
    Shao, Bin
    Dong, Hang
    Zheng, Tiantian
    Du, Pan
    Jia, Shidong
    King, Bonnie
    Wang, Jing
    Liu, Xiaoran
    Li, Huiping
    CANCER RESEARCH, 2023, 83 (05)
  • [8] Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive (HR+)/HER2 receptor-negative (HER2-) metastatic breast cancer (MBC): A real life multicenter Italian study
    Palumbo, R.
    Torrisi, R.
    Quaquarini, E.
    Sottotetti, F.
    Gambaro, A.
    Collova, E.
    Ferzi, A.
    Fava, S.
    Agostinetto, E.
    Tagliaferri, B.
    Licata, L.
    Teragni, C.
    Bernardo, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [9] Circulating tumor DNA (ctDNA) mutation (mut) profile in relation to paboclicib (pal) efficacy in hormone receptor positive (HR+) and HER2 negative (HER2-) metastatic breast cancer (MBC)
    Xi, Jing
    Bagegni, Nusayba
    Ademuyiwa, Foluso
    Frith, Ashley
    Suresh, Rama
    Roshal, Anna
    Rigden, Caron
    Hernandez-Aya, Leonel
    Peterson, Lindsay
    Opyrchal, Mateusz
    Clifton, Katherine
    Weilbaecher, Katherine
    Bose, Ron
    Ma, Cynthia
    CANCER RESEARCH, 2021, 81 (04)
  • [10] A phase II trial assessing the safety of an alternative dosing schedule of palbociclib (palbo) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC): Alt Dose Palbo
    Krishnamurthy, Jairam
    Luo, Jingqin
    Ademuyiwa, Foluso
    Suresh, Rama
    Rigden, Caron
    Reardon, Timothy
    Weilbaecher, Katherine
    Frith, Ashley
    Roshal, Anna
    Tandra, Pavan
    Cherian, Mathew
    Summa, Tracy
    Thomas, Shana
    Hernandez-Aya, Leonel
    Peterson, Lindsay
    Ma, Cynthia
    CANCER RESEARCH, 2020, 80 (04)
12345